Emerging antimicrobial resistances among Proteus mirabilis in Europe: Report from the MYSTIC Program (1997-2001)

Journal of Chemotherapy

Volumn 14, Issue 3, 2002, Pages 253-258

  Mutnick, Alan H ^a   Turner, P J ^a   Jones, R N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

European antimicrobial resistance patterns; Meropenem; MYSTIC; P. mirabilis; Resistance

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; DRUG DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; TAZOBACTAM; THIENAMYCIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CYSTIC FIBROSIS; EUROPE; INTENSIVE CARE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; PROTEUS MIRABILIS; CLASSIFICATION; DRUG EFFECT; GRAM NEGATIVE INFECTION; HEALTH SURVEY; HUMAN; INFORMATION PROCESSING; MICROBIOLOGICAL EXAMINATION;

ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CEPHALOSPORINS; CIPROFLOXACIN; CYSTIC FIBROSIS; DATA COLLECTION; DRUG RESISTANCE, BACTERIAL; EUROPE; HUMANS; IMIPENEM; INTENSIVE CARE; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; PENICILLANIC ACID; PIPERACILLIN; POPULATION SURVEILLANCE; PROTEUS INFECTIONS; PROTEUS MIRABILIS; THIENAMYCINS;

EID: 0036598902     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2002.14.3.253     Document Type: Article

References (21)

1. Detection of emerging resistance patterns within longitudinal surveillance systems: Data sensitivity and microbial susceptibility
2. Hospital-acquired infections: Diseases with increasingly limited therapies
3. Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms
4. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: Implications for the clinical microbiology laboratory
5. Beta-lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa
6. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: Comparison of antibiotic susceptibilities between countries and centre types
7. Diversity of TEM mutants in Proteus mirabilis
8. Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center
9. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations
10. Extended-spectrum β-lactamase in Proteus mirabilis
11. TEM-72, a new extended-spectrum beta-lactamase detected in Proteus mirabilis and Morganella morganii in Italy
12. In vitro and in vivo transferable beta-lactam resistance due to a new plasmid-mediated oxyminocephalosporinase from a clinical isolate of Proteus mirabilis
13. Prevalence of beta-lactamases among 1,072 clinical strains of Proteus mirabilis: A 2-year survey in a French hospital
14. Clinical relevance of Proteus mirabilis in hospital patients: A two year survey
15. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): A global overview
16. The MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) programme
17. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated worldwide
18. A review of the in vitro spectrum of imipenem
19. A multicenter in vitro evaluation of SM-7338: A new carbapenem